Essentials of SGLT2 Inhibitors in Diabetes (eBook)

eBook Download: PDF
2016 | 1st ed. 2016
XI, 68 Seiten
Springer International Publishing (Verlag)
978-3-319-43296-0 (ISBN)

Lese- und Medienproben

Essentials of SGLT2 Inhibitors in Diabetes - Miles Fisher, Gerard McKay
Systemvoraussetzungen
53,49 inkl. MwSt
  • Download sofort lieferbar
  • Zahlungsarten anzeigen

Written by experts in the field, this clinical handbook explores the novel SGLT2 drug class for the treatment of diabetes. This book includes evidence-based guidelines, major clinical trials, and a discussion of treatment options currently available, as well as those currently in development. Essentials of SGLT2 Inhibitors is an ideal educational resource for busy medical professionals who need to stay up-to-date with diabetes treatment advances in order to provide the best possible clinical care for their patients.



Professor Miles Fisher graduated from the University of Glasgow in 1979, where he received his MD in 1988 for his thesis on 'Evidence for a Diabetic Cardiopathy.' He has been a consultant physician at Glasgow Royal Infirmary since 2001. In 2010, he was made an Honorary Professor at the University of Glasgow. He was a Vice-President (Medical) of the Royal College of Physicians and Surgeons of Glasgow from 2011-2014. Professor Fisher is the current President of the Scottish Society of Physicians. He interests include diabetes and the heart, hypoglycemia, and new treatments for diabetes, and he is the author or co-author of over 70 original papers, over 60 review articles, and over 40 book chapters. He was on the steering committee of the DIGAMI 2 study as the Scottish coordinator, as well as an events adjudicator for the HOPE and HOPE-TOO studies, and is currently an events adjudicator for the ACE Trial.

Professor Gerald (Gerry) McKay studied medicine at the University of Glasgow with subsequent training in the west of Scotland before undertaking specialty training in clinical pharmacology and therapeutics in Newcastle upon Tyne. Additional specialty training included specific training in diabetes and cardiovascular risk management. As an Association of the British Pharmaceutical Industry (ABPI)-sponsored trainee, Professor McKay spent a year in industry with Pfizer gaining experience in all aspects of drug development. He also had a secondment to the National Institute for Health and Clinical Excellence (NICE).  After 3 years as a consultant in a busy district general hospital, in 2007 Professor McKay became a Consultant Physician and Clinical Pharmacologist at Glasgow Royal Infirmary. He contributes to the provision of diabetes care in the north east of Glasgow with a specialist interest in type 2 diabetes and diabetic nephropathy, as well as an interest in safe and rational prescribing. He has considerable commitment to undergraduate and postgraduate education at the University of Glasgow and University of Strathclyde where he holds honorary positions. Additionally, he is Vice Chair of NHS Greater Glasgow and Clyde's Area Drug and Therapeutics committee and served for 7 years on the New Drugs Committee of the Scottish Medicines Consortium. Professor McKay is the co-editor of a major undergraduate textbook on clinical pharmacology and has published numerous papers in the field of diabetes and therapeutics.

Jenna L Cowan, MbChB, BSc (Med Sci), MRCP has been a specialty registrar in Diabetes and Endocrinology in the West of Scotland Deanery since 2008. She qualified from the University of Glasgow in 2004 and is currently completing her final specialty training at the Queen Elizabeth University Hospital in Glasgow. Her clinical interests include genetic and gestational diabetes.

Professor Miles Fisher graduated from the University of Glasgow in 1979, where he received his MD in 1988 for his thesis on ‘Evidence for a Diabetic Cardiopathy.’ He has been a consultant physician at Glasgow Royal Infirmary since 2001. In 2010, he was made an Honorary Professor at the University of Glasgow. He was a Vice-President (Medical) of the Royal College of Physicians and Surgeons of Glasgow from 2011-2014. Professor Fisher is the current President of the Scottish Society of Physicians. He interests include diabetes and the heart, hypoglycemia, and new treatments for diabetes, and he is the author or co-author of over 70 original papers, over 60 review articles, and over 40 book chapters. He was on the steering committee of the DIGAMI 2 study as the Scottish coordinator, as well as an events adjudicator for the HOPE and HOPE-TOO studies, and is currently an events adjudicator for the ACE Trial.Professor Gerald (Gerry) McKay studied medicine at the University of Glasgow with subsequent training in the west of Scotland before undertaking specialty training in clinical pharmacology and therapeutics in Newcastle upon Tyne. Additional specialty training included specific training in diabetes and cardiovascular risk management. As an Association of the British Pharmaceutical Industry (ABPI)-sponsored trainee, Professor McKay spent a year in industry with Pfizer gaining experience in all aspects of drug development. He also had a secondment to the National Institute for Health and Clinical Excellence (NICE).  After 3 years as a consultant in a busy district general hospital, in 2007 Professor McKay became a Consultant Physician and Clinical Pharmacologist at Glasgow Royal Infirmary. He contributes to the provision of diabetes care in the north east of Glasgow with a specialist interest in type 2 diabetes and diabetic nephropathy, as well as an interest in safe and rational prescribing. He has considerable commitment to undergraduate and postgraduate education at the University of Glasgow and University of Strathclyde where he holds honorary positions. Additionally, he is Vice Chair of NHS Greater Glasgow and Clyde’s Area Drug and Therapeutics committee and served for 7 years on the New Drugs Committee of the Scottish Medicines Consortium. Professor McKay is the co-editor of a major undergraduate textbook on clinical pharmacology and has published numerous papers in the field of diabetes and therapeutics.Jenna L Cowan, MbChB, BSc (Med Sci), MRCP has been a specialty registrar in Diabetes and Endocrinology in the West of Scotland Deanery since 2008. She qualified from the University of Glasgow in 2004 and is currently completing her final specialty training at the Queen Elizabeth University Hospital in Glasgow. Her clinical interests include genetic and gestational diabetes.

Overview of Type 2 Diabetes.- SGLT2 Inhibitors for Treating Diabetes.- Guidelines for the Treatment of Type 2 Diabetes Mellitus.- Using SGLT2 Inhibitors in Special Populations.

Erscheint lt. Verlag 14.11.2016
Zusatzinfo XI, 68 p. 13 illus. in color.
Verlagsort Cham
Sprache englisch
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Allgemeinmedizin
Medizin / Pharmazie Medizinische Fachgebiete Innere Medizin
Schlagworte canagliflozin • dapagliflozin • Diabetes • empagliflozin • SGLT2 • Sodium-glucose transport proteins • type 2 diabetes
ISBN-10 3-319-43296-6 / 3319432966
ISBN-13 978-3-319-43296-0 / 9783319432960
Haben Sie eine Frage zum Produkt?
PDFPDF (Wasserzeichen)
Größe: 1,7 MB

DRM: Digitales Wasserzeichen
Dieses eBook enthält ein digitales Wasser­zeichen und ist damit für Sie persona­lisiert. Bei einer missbräuch­lichen Weiter­gabe des eBooks an Dritte ist eine Rück­ver­folgung an die Quelle möglich.

Dateiformat: PDF (Portable Document Format)
Mit einem festen Seiten­layout eignet sich die PDF besonders für Fach­bücher mit Spalten, Tabellen und Abbild­ungen. Eine PDF kann auf fast allen Geräten ange­zeigt werden, ist aber für kleine Displays (Smart­phone, eReader) nur einge­schränkt geeignet.

Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen dafür einen PDF-Viewer - z.B. den Adobe Reader oder Adobe Digital Editions.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen dafür einen PDF-Viewer - z.B. die kostenlose Adobe Digital Editions-App.

Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.

Mehr entdecken
aus dem Bereich